Format
Items per page
Sort by

Send to:

Choose Destination

Links from PubMed

Items: 1 to 20 of 135

1.

Linezolid for multidrug-resistant tuberculosis.

Cox H, Ford N, Hughes J, Goemaere E.

Lancet Infect Dis. 2013 Jan;13(1):16. doi: 10.1016/S1473-3099(12)70299-2. No abstract available.

PMID:
23257228
2.

Linezolid for multidrug-resistant tuberculosis.

Chang KC, Leung CC, Daley CL.

Lancet Infect Dis. 2012 Jul;12(7):502-3. doi: 10.1016/S1473-3099(12)70137-8. No abstract available.

PMID:
22742623
3.

Linezolid for multidrug-resistant tuberculosis - authors' reply.

Chang KC, Leung CC, Daley CL.

Lancet Infect Dis. 2013 Jan;13(1):16-7. doi: 10.1016/S1473-3099(12)70272-4. No abstract available.

PMID:
23257227
4.

Comment on: Daily 300 mg dose of linezolid for the treatment of intractable multidrug-resistant and extensively drug-resistant tuberculosis.

Yew WW, Chang KC, Chau CH.

J Antimicrob Chemother. 2009 Nov;64(5):1119; author reply 1119-20. doi: 10.1093/jac/dkp291. Epub 2009 Aug 8. No abstract available.

5.

Daily 300 mg dose of linezolid for the treatment of intractable multidrug-resistant and extensively drug-resistant tuberculosis--authors' response.

Koh WJ, Shim TS.

J Antimicrob Chemother. 2009 Nov;64(5):1119-20. doi: 10.1093/jac/dkp344. Epub 2009 Sep 10. No abstract available.

6.

Low minimal inhibitory concentrations of linezolid against multidrug-resistant tuberculosis strains.

Sotgiu G, Centis R, D'Ambrosio L, Castiglia P, Migliori GB.

Eur Respir J. 2015 Jan;45(1):287-9. doi: 10.1183/09031936.00135014. No abstract available.

PMID:
25552740
7.

Low minimal inhibitory concentrations of linezolid against multidrug-resistant tuberculosis strains.

Weiss T, Schönfeld N, Otto-Knapp R, Bös L, Bettermann G, Mauch H, Bauer TT, Rüssmann H.

Eur Respir J. 2015 Jan;45(1):285-7. doi: 10.1183/09031936.00084614. No abstract available.

PMID:
25552739
8.

Linezolid in the treatment of drug-resistant tuberculosis: the way forward?

Yew WW, Lange C.

Int J Tuberc Lung Dis. 2014 Jun;18(6):631-2. doi: 10.5588/ijtld.14.0191. No abstract available.

PMID:
24903928
9.

[The analysis of clinical data about the treatment of linezolid against tuberculosis].

Nie WJ, Chu NH.

Zhonghua Jie He He Hu Xi Za Zhi. 2013 Aug;36(8):601-3. Review. Chinese. No abstract available.

PMID:
24252739
10.

Linezolid to treat extensively drug-resistant TB: retrospective data are confirmed by experimental evidence.

Sotgiu G, Centis R, D'Ambrosio L, Spanevello A, Migliori GB; International Group for the study of Linezolid.

Eur Respir J. 2013 Jul;42(1):288-90. doi: 10.1183/09031936.00191712. No abstract available.

11.

[Multiresistant tuberculosis caused by Mycobacterium bovis and human immunodeficiency virus infection. Are there new therapeutic possibilities?].

Valencia ME, Moreno V, Laguna F, González-Lahoz JM.

Enferm Infecc Microbiol Clin. 2001 Jan;19(1):37-9. Spanish. No abstract available.

PMID:
11256251
12.

Linezolid-containing regimens for the treatment of drug-resistant tuberculosis in South African children.

Rose PC, Hallbauer UM, Seddon JA, Hesseling AC, Schaaf HS.

Int J Tuberc Lung Dis. 2012 Dec;16(12):1588-93. doi: 10.5588/ijtld.12.0322. Epub 2012 Oct 2.

PMID:
23032215
13.

Can intermittent dosing optimize prolonged linezolid treatment of difficult multidrug-resistant tuberculosis?

Chang KC, Yew WW, Cheung SW, Leung CC, Tam CM, Chau CH, Wen PK, Chan RC.

Antimicrob Agents Chemother. 2013 Jul;57(7):3445-9. doi: 10.1128/AAC.00388-13. Epub 2013 May 6.

14.

Fatal lactic acidosis after prolonged linezolid exposure for treatment of multidrug-resistant tuberculosis.

Boutoille D, Grossi O, Depatureaux A, Tattevin P.

Eur J Intern Med. 2009 Oct;20(6):e134-5. doi: 10.1016/j.ejim.2008.12.002. Epub 2009 Jan 23. No abstract available.

PMID:
19782904
15.

Treatment of multidrug-resistant and extensively drug-resistant tuberculosis in adolescent patients.

Rodrigues M, Brito M, Villar M, Correia P.

Pediatr Infect Dis J. 2014 Jun;33(6):657-9. doi: 10.1097/INF.0000000000000341.

PMID:
24642519
16.

Linezolid in the treatment of multidrug-resistant tuberculosis.

Schecter GF, Scott C, True L, Raftery A, Flood J, Mase S.

Clin Infect Dis. 2010 Jan 1;50(1):49-55. doi: 10.1086/648675.

17.

Justifying research risks in a clinical trial for treatment of multidrug-resistant tuberculosis.

Heilig CM, Chia D, El-Sadr WM, Hirsch-Moverman Y, Kenzie WR, Saukkonen J, Villarino ME, Padayatchi N.

IRB. 2011 Jul-Aug;33(4):10-7. No abstract available.

PMID:
21932482
18.

Linezolid in the treatment of 'difficult' multidrug-resistant tuberculosis.

Yew WW, Chau CH, Wen KH.

Int J Tuberc Lung Dis. 2008 Mar;12(3):345-6. No abstract available.

PMID:
18284844
19.

Comment on: Daily 300 mg dose of linezolid for the treatment of intractable multidrug-resistant and extensively drug-resistant tuberculosis.

Sotgiu G, Lange C, Richardson MD, Matteelli A, Centis R, Eker B, Guenther G, Spanevello A, Migliori GB; TBNET.

J Antimicrob Chemother. 2009 Oct;64(4):879-83; author reply 883-4. doi: 10.1093/jac/dkp265. Epub 2009 Aug 3. No abstract available.

20.

A retrospective TBNET assessment of linezolid safety, tolerability and efficacy in multidrug-resistant tuberculosis.

Migliori GB, Eker B, Richardson MD, Sotgiu G, Zellweger JP, Skrahina A, Ortmann J, Girardi E, Hoffmann H, Besozzi G, Bevilacqua N, Kirsten D, Centis R, Lange C; TBNET Study Group.

Eur Respir J. 2009 Aug;34(2):387-93. doi: 10.1183/09031936.00009509. Epub 2009 Mar 12.

Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk